• OTS
  • February 16, 2021
SHARE
Post Views: 981

Winkelsas AM, Grunseich C, Harmison GG, Chwalenia K, Rinaldi C, Hammond SM, Johnson K, Bowerman M, Arya S, Talbot K, Wood MJ, Fischbeck KH.

Mol Ther Nucleic Acids. 2021 Jan 5;23:731-742.

Pubmed

Related articles

A targeted antisense therapeutic approach for Hutchinson-Gilford progeria syndrome

A targeted antisense therapeutic approach for Hutchinson-Gilford progeria syndrome

April 23rd, 2021
Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson-Gilford progeria syndrome

Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson-Gilford progeria syndrome

April 23rd, 2021
α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease

α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease

April 23rd, 2021
Antisense oligonucleotide therapy in a humanized mouse model of MECP2 duplication syndrome

Antisense oligonucleotide therapy in a humanized mouse model of MECP2 duplication syndrome

April 23rd, 2021
Perspectives on the Designation of Oligonucleotide Starting Materials

Perspectives on the Designation of Oligonucleotide Starting Materials

March 15th, 2021
Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents

Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents

March 15th, 2021